EZH2对FADS2的差异调控揭示了卵巢癌治疗中的代谢脆弱性。

IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
EBioMedicine Pub Date : 2025-09-01 Epub Date: 2025-08-15 DOI:10.1016/j.ebiom.2025.105879
Zhengyang Guo, Yuqing Wang, Jiagui Song, Ying Song, Yang Bai, Yinjia Li, Jianling Yang, Tong Liu, Lijun Ma, Celina G Kleer, Xiao Huo, Lixiang Xue
{"title":"EZH2对FADS2的差异调控揭示了卵巢癌治疗中的代谢脆弱性。","authors":"Zhengyang Guo, Yuqing Wang, Jiagui Song, Ying Song, Yang Bai, Yinjia Li, Jianling Yang, Tong Liu, Lijun Ma, Celina G Kleer, Xiao Huo, Lixiang Xue","doi":"10.1016/j.ebiom.2025.105879","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OC) is the most aggressive and lethal gynaecological cancer and is characterised by abnormal lipid metabolism. Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It functions as a tumour promoter through both canonical H3K27me3 modification and noncanonical mechanisms. Although EZH2 has been developed as a potential anticancer target, the therapeutic effects of EZH2 inhibitors in solid tumours are still limited.</p><p><strong>Methods: </strong>The levels of fatty acid and tricarboxylic acid (TCA) cycle-related metabolites were measured via high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). EZH2-knockout cells, ChIP‒qPCR, qPCR, and western blotting were used to investigate the regulatory effect of EZH2 on FADS2. The expression of FADS2 transcript variants and their correlations with prognosis in clinical OC tissues were analysed via the GEPIA 2 database. Various OC cell lines, patient-derived organoids and tumour-bearing models have been used to test the therapeutic effects of EZH2 and FADS2 inhibitors. 4D-DIA proteomics, the Seahorse assay and flow cytometry-based detection of mitochondrial function and protein synthesis were performed to explore the mechanism of combined therapy.</p><p><strong>Findings: </strong>EZH2 knockout increased FADS2 variant 1 (v1) and decreased variant 2/3 (v2/3) at both the mRNA and protein levels. EZH2 occupied the promoters of FADS2 v1 and v2/3, but the enrichment of H3K27me3 at the v2/v3 promoter was significantly lower than that at the v1 promoter. Furthermore, EZH2 inhibitors increased full-length FADS2 v1 expression and polyunsaturated fatty acid abundance in OC cells. A high FADS2 v1/v2 ratio was associated with poor prognosis in patients with OC. Targeting FADS2 with shRNAs or inhibitors reduced EZH2 levels and sensitised cancer cells to EZH2 inhibitors. The combined inhibition of EZH2 and FADS2 induced mitochondrial dysfunction and energy stress and synergised to reduce tumour growth in vitro and in vivo.</p><p><strong>Interpretation: </strong>EZH2 inhibition increases the proportion of the full FADS2 isoform through differential regulation, which suggests a poor prognosis in OC patients. Simultaneous inhibition of EZH2 and FADS2 causes mitochondrial dysfunction and energy stress in OC, resulting in a more pronounced antitumour effect. Our study reveals a mechanistic connection between EZH2 and FADS2 and provides a potential therapeutic strategy for OC.</p><p><strong>Funding: </strong>This work was supported by the Youth Program of the National Natural Science Foundation of China (No. 82203102, No. 82303801, No. 82203433), the National Key Research and Development Program of China (2022YFA1104001), the General Program of the National Natural Science Foundation of China (No. 82272745, No. 82072870, No. 81972966, No. 82373173, No. 82073057), and the Peking University Third Hospital Clinical Key Project (BYSY2022069, BYSY2022070, BYSYZD2023010).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"119 ","pages":"105879"},"PeriodicalIF":10.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391508/pdf/","citationCount":"0","resultStr":"{\"title\":\"Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment.\",\"authors\":\"Zhengyang Guo, Yuqing Wang, Jiagui Song, Ying Song, Yang Bai, Yinjia Li, Jianling Yang, Tong Liu, Lijun Ma, Celina G Kleer, Xiao Huo, Lixiang Xue\",\"doi\":\"10.1016/j.ebiom.2025.105879\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ovarian cancer (OC) is the most aggressive and lethal gynaecological cancer and is characterised by abnormal lipid metabolism. Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It functions as a tumour promoter through both canonical H3K27me3 modification and noncanonical mechanisms. Although EZH2 has been developed as a potential anticancer target, the therapeutic effects of EZH2 inhibitors in solid tumours are still limited.</p><p><strong>Methods: </strong>The levels of fatty acid and tricarboxylic acid (TCA) cycle-related metabolites were measured via high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). EZH2-knockout cells, ChIP‒qPCR, qPCR, and western blotting were used to investigate the regulatory effect of EZH2 on FADS2. The expression of FADS2 transcript variants and their correlations with prognosis in clinical OC tissues were analysed via the GEPIA 2 database. Various OC cell lines, patient-derived organoids and tumour-bearing models have been used to test the therapeutic effects of EZH2 and FADS2 inhibitors. 4D-DIA proteomics, the Seahorse assay and flow cytometry-based detection of mitochondrial function and protein synthesis were performed to explore the mechanism of combined therapy.</p><p><strong>Findings: </strong>EZH2 knockout increased FADS2 variant 1 (v1) and decreased variant 2/3 (v2/3) at both the mRNA and protein levels. EZH2 occupied the promoters of FADS2 v1 and v2/3, but the enrichment of H3K27me3 at the v2/v3 promoter was significantly lower than that at the v1 promoter. Furthermore, EZH2 inhibitors increased full-length FADS2 v1 expression and polyunsaturated fatty acid abundance in OC cells. A high FADS2 v1/v2 ratio was associated with poor prognosis in patients with OC. Targeting FADS2 with shRNAs or inhibitors reduced EZH2 levels and sensitised cancer cells to EZH2 inhibitors. The combined inhibition of EZH2 and FADS2 induced mitochondrial dysfunction and energy stress and synergised to reduce tumour growth in vitro and in vivo.</p><p><strong>Interpretation: </strong>EZH2 inhibition increases the proportion of the full FADS2 isoform through differential regulation, which suggests a poor prognosis in OC patients. Simultaneous inhibition of EZH2 and FADS2 causes mitochondrial dysfunction and energy stress in OC, resulting in a more pronounced antitumour effect. Our study reveals a mechanistic connection between EZH2 and FADS2 and provides a potential therapeutic strategy for OC.</p><p><strong>Funding: </strong>This work was supported by the Youth Program of the National Natural Science Foundation of China (No. 82203102, No. 82303801, No. 82203433), the National Key Research and Development Program of China (2022YFA1104001), the General Program of the National Natural Science Foundation of China (No. 82272745, No. 82072870, No. 81972966, No. 82373173, No. 82073057), and the Peking University Third Hospital Clinical Key Project (BYSY2022069, BYSY2022070, BYSYZD2023010).</p>\",\"PeriodicalId\":11494,\"journal\":{\"name\":\"EBioMedicine\",\"volume\":\"119 \",\"pages\":\"105879\"},\"PeriodicalIF\":10.8000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391508/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EBioMedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ebiom.2025.105879\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EBioMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ebiom.2025.105879","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:卵巢癌(OC)是最具侵袭性和致死性的妇科肿瘤,以脂质代谢异常为特征。zeste同源物2增强剂(EZH2)是多梳抑制复合物2 (PRC2)的催化亚基。它通过典型的H3K27me3修饰和非典型机制作为肿瘤启动子起作用。尽管EZH2已被开发为潜在的抗癌靶点,但EZH2抑制剂在实体瘤中的治疗作用仍然有限。方法:采用高效液相色谱-串联质谱法(HPLC-MS/MS)测定脂肪酸和三羧酸(TCA)循环相关代谢物的含量。采用EZH2敲除细胞、ChIP-qPCR、qPCR和western blotting检测EZH2对FADS2的调控作用。通过GEPIA 2数据库分析临床OC组织中FADS2转录变异体的表达及其与预后的相关性。各种OC细胞系、患者来源的类器官和荷瘤模型已被用来测试EZH2和FADS2抑制剂的治疗效果。通过4D-DIA蛋白质组学、海马实验和流式细胞术检测线粒体功能和蛋白质合成,探讨联合治疗的机制。结果:EZH2基因敲除增加了FADS2变异1 (v1),降低了变异2/3 (v2/3)的mRNA和蛋白水平。EZH2占据了FADS2 v1和v2/3的启动子,但H3K27me3在v2/v3启动子的富集量明显低于v1启动子。此外,EZH2抑制剂增加了OC细胞中FADS2 v1的全长表达和多不饱和脂肪酸的丰度。高FADS2 v1/v2比值与OC患者预后不良相关。用shrna或抑制剂靶向FADS2可降低EZH2水平,并使癌细胞对EZH2抑制剂敏感。EZH2和FADS2的联合抑制诱导线粒体功能障碍和能量应激,并协同抑制肿瘤生长。解释:EZH2抑制通过差异调控增加了FADS2全亚型的比例,提示OC患者预后较差。同时抑制EZH2和FADS2导致OC线粒体功能障碍和能量应激,从而产生更明显的抗肿瘤作用。我们的研究揭示了EZH2和FADS2之间的机制联系,并为OC提供了潜在的治疗策略。国家自然科学基金青年项目(No. 82203102, No. 82303801, No. 82203433),国家重点研发计划项目(No. 2022YFA1104001),国家自然科学基金一般项目(No. 82272745, No. 82072870, No. 81972966, No. 82373173, No. 82073057),北京大学第三医院临床重点项目(BYSY2022069, BYSY2022070, BYSYZD2023010)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment.

Background: Ovarian cancer (OC) is the most aggressive and lethal gynaecological cancer and is characterised by abnormal lipid metabolism. Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It functions as a tumour promoter through both canonical H3K27me3 modification and noncanonical mechanisms. Although EZH2 has been developed as a potential anticancer target, the therapeutic effects of EZH2 inhibitors in solid tumours are still limited.

Methods: The levels of fatty acid and tricarboxylic acid (TCA) cycle-related metabolites were measured via high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). EZH2-knockout cells, ChIP‒qPCR, qPCR, and western blotting were used to investigate the regulatory effect of EZH2 on FADS2. The expression of FADS2 transcript variants and their correlations with prognosis in clinical OC tissues were analysed via the GEPIA 2 database. Various OC cell lines, patient-derived organoids and tumour-bearing models have been used to test the therapeutic effects of EZH2 and FADS2 inhibitors. 4D-DIA proteomics, the Seahorse assay and flow cytometry-based detection of mitochondrial function and protein synthesis were performed to explore the mechanism of combined therapy.

Findings: EZH2 knockout increased FADS2 variant 1 (v1) and decreased variant 2/3 (v2/3) at both the mRNA and protein levels. EZH2 occupied the promoters of FADS2 v1 and v2/3, but the enrichment of H3K27me3 at the v2/v3 promoter was significantly lower than that at the v1 promoter. Furthermore, EZH2 inhibitors increased full-length FADS2 v1 expression and polyunsaturated fatty acid abundance in OC cells. A high FADS2 v1/v2 ratio was associated with poor prognosis in patients with OC. Targeting FADS2 with shRNAs or inhibitors reduced EZH2 levels and sensitised cancer cells to EZH2 inhibitors. The combined inhibition of EZH2 and FADS2 induced mitochondrial dysfunction and energy stress and synergised to reduce tumour growth in vitro and in vivo.

Interpretation: EZH2 inhibition increases the proportion of the full FADS2 isoform through differential regulation, which suggests a poor prognosis in OC patients. Simultaneous inhibition of EZH2 and FADS2 causes mitochondrial dysfunction and energy stress in OC, resulting in a more pronounced antitumour effect. Our study reveals a mechanistic connection between EZH2 and FADS2 and provides a potential therapeutic strategy for OC.

Funding: This work was supported by the Youth Program of the National Natural Science Foundation of China (No. 82203102, No. 82303801, No. 82203433), the National Key Research and Development Program of China (2022YFA1104001), the General Program of the National Natural Science Foundation of China (No. 82272745, No. 82072870, No. 81972966, No. 82373173, No. 82073057), and the Peking University Third Hospital Clinical Key Project (BYSY2022069, BYSY2022070, BYSYZD2023010).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
EBioMedicine
EBioMedicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
17.70
自引率
0.90%
发文量
579
审稿时长
5 weeks
期刊介绍: eBioMedicine is a comprehensive biomedical research journal that covers a wide range of studies that are relevant to human health. Our focus is on original research that explores the fundamental factors influencing human health and disease, including the discovery of new therapeutic targets and treatments, the identification of biomarkers and diagnostic tools, and the investigation and modification of disease pathways and mechanisms. We welcome studies from any biomedical discipline that contribute to our understanding of disease and aim to improve human health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信